*Correspondence: Xian-Feng Zhang, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Semaglutide (GLP1-S) is evaluated in laboratory research for: Its selective GLP-1 receptor agonist activity differentiates it from multi-receptor metabolic peptides studied in other research frameworks
Clinically, steady state often correlates with a stabilization of side effects
The tissue does not care which specific medication was injected there, only that it was punctured and exposed to a foreign substance
GLP-1 medications arent controlled substances, which means licensed physicians can evaluate you and prescribe them through a telehealth visit in most states
Free, no obligation and no Medicare card needed
